Cargando…

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial

As most erb‐b2 receptor tyrosine kinase 2 (HER2)‐positive breast cancer (BC) patients currently receive dual HER2‐targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salvage therapy, are needed. Herein, we evaluated the 41‐gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Triulzi, Tiziana, Bianchini, Giampaolo, Di Cosimo, Serena, Pienkowski, Tadeusz, Im, Young‐Hyuck, Bianchi, Giulia Valeria, Galbardi, Barbara, Dugo, Matteo, De Cecco, Loris, Tseng, Ling‐Ming, Liu, Mei‐Ching, Bermejo, Begoña, Semiglazov, Vladimir, Viale, Giulia, de la Haba‐Rodriguez, Juan, Oh, Do‐Youn, Poirier, Brigitte, Valagussa, Pinuccia, Gianni, Luca, Tagliabue, Elda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208076/ https://www.ncbi.nlm.nih.gov/pubmed/34816585 http://dx.doi.org/10.1002/1878-0261.13141

Ejemplares similares

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
por: Pizzamiglio, Sara, et al.
Publicado: (2021)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment
por: Rybinska, Ilona, et al.
Publicado: (2020)

Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients
por: Retsky, Michael, et al.
Publicado: (2004)

TraR, a Homolog of a RNAP Secondary Channel Interactor, Modulates Transcription
por: Blankschien, Matthew D., et al.
Publicado: (2009)

Theoretical Study of Molecular Determinants Involved in Signal Binding to the TraR Protein of Agrobacterium tumefaciens
por: Goh, Wai-Kean, et al.
Publicado: (2005)

E. coli TraR allosterically regulates transcription initiation by altering RNA polymerase conformation
por: Chen, James, et al.
Publicado: (2019)

Modulation of DNA repair genes induced by TLR9 agonists: A strategy to eliminate “altered” cells?
por: Sommariva, Michele, et al.
Publicado: (2012)

Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
por: Di Modica, Martina, et al.
Publicado: (2017)

HER2 mRNA Levels, Estrogen Receptor Activity and Susceptibility to Trastuzumab in Primary Breast Cancer
por: Triulzi, Tiziana, et al.
Publicado: (2022)

“Omics” and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas
por: Tagliabue, Elda, et al.
Publicado: (2014)

Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors
por: Giussani, Marta, et al.
Publicado: (2019)

Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences
por: Rybinska, Ilona, et al.
Publicado: (2021)

Spatial predictors of immunotherapy response in triple-negative breast cancer
por: Wang, Xiao Qian, et al.
Publicado: (2023)

The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective
por: Fogazzi, Valentina, et al.
Publicado: (2022)

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer
por: Viganò, Lucia, et al.
Publicado: (2022)

Adipocytes in Breast Cancer, the Thick and the Thin
por: Rybinska, Ilona, et al.
Publicado: (2020)

Homologs of the Escherichia coli F Element Protein TraR, Including Phage Lambda Orf73, Directly Reprogram Host Transcription
por: Gopalkrishnan, Saumya, et al.
Publicado: (2022)

Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour
por: Demicheli, Romano, et al.
Publicado: (2004)

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
por: Di Modica, Martina, et al.
Publicado: (2022)

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer
por: Castagnoli, L, et al.
Publicado: (2017)

Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2018)

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
por: Castagnoli, Lorenzo, et al.
Publicado: (2019)

Optimizing (neo)adjuvant treatment of HER2-positive breast cancer
por: Basho, Reva K., et al.
Publicado: (2018)

The Educational Program of Macrophages toward a Hyperprogressive Disease-Related Phenotype Is Orchestrated by Tumor-Derived Extracellular Vesicles
por: Indino, Serena, et al.
Publicado: (2022)

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
por: Triulzi, Tiziana, et al.
Publicado: (2015)

Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Ocaña, Alberto, et al.
Publicado: (2022)

Expression Profile of Tyrosine Phosphatases in HER2 Breast Cancer Cells and Tumors
por: Lucci, Maria Antonietta, et al.
Publicado: (2010)

Infrared Spectroscopic Imaging Visualizes a Prognostic Extracellular Matrix-Related Signature in Breast Cancer
por: Tiwari, Saumya, et al.
Publicado: (2020)

Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
por: Di Modica, Martina, et al.
Publicado: (2015)

Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2023)

Local Administration of Caloric Restriction Mimetics to Promote the Immune Control of Lung Metastases
por: Le Noci, Valentino, et al.
Publicado: (2019)

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
por: Swain, Sandra M., et al.
Publicado: (2022)

Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation
por: De Cecco, Loris, et al.
Publicado: (2013)

Quorum‐dependent transfer of the opine‐catabolic plasmid pAoF64/95 is regulated by a novel mechanism involving inhibition of the TraR antiactivator TraM
por: Wetzel, Margaret E., et al.
Publicado: (2018)

Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype
por: Huang, Xiaoyan, et al.
Publicado: (2015)

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
por: Eustace, A. J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vtod5v8q0areqg6jo3i0t39pnp